Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 5/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701981 | 0.71 | NOS1 (0.51) | ADRA1DADRA1AADRA1BHTR2AKDM4E | |
| SCHEMBL7480247 | 0.70 | GRIN2B (0.40) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| SCHEMBL6700692 | 0.65 | NOS1 (0.52) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| SCHEMBL4168502 | 0.63 | KDM4E (0.52) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6703574 | 0.61 | NOS1 (0.48) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27567942 | 0.60 | ADRA1D (0.49) | ADRA1DADRA1AADRA1BADRB2ADRB1 | |
| SCHEMBL9179569 | 0.59 | HTR2A (0.82) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6699624 | 0.59 | NOS1 (0.60) | ADRA1DADRA1AADRA1B | |
| SCHEMBL4167478 | 0.59 | GAA (0.50) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4164330 | 0.59 | KDM4E (0.58) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1007512-B1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PROD INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6362195-B1 | INHIBITOR OF NITRIC OXIDE SYNTHASE; CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-03-26 | — | — | US | disclosed |
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | LOWE JOHN ADAMS (US) | 2002-02-21 | — | — | US | disclosed |
| EP-1109556-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1007512-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-2000009130-A2 | NEW PHARMACEUTICAL USES FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999011620-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | NOS3, NOS2, PNMT | ADRA1D 47/4885ADRA1A 67/4885ADRA1B 96/4885 |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | ADRA1D 814/4885ADRA1A 558/4885ADRA1B 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.